PDS Biotechnology (PDSB) News Today $1.75 -0.04 (-2.23%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.29%) As of 06/13/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Q2 EPS Estimate for PDS Biotechnology Decreased by AnalystJune 15 at 1:45 AM | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday.June 14 at 2:03 AM | marketbeat.comHC Wainwright Expects Reduced Earnings for PDS BiotechnologyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at HC Wainwright decreased their Q2 2025 EPS estimates for PDS Biotechnology in a report released on Wednesday, June 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.25) forJune 13 at 5:50 AM | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC WainwrightJune 12 at 3:33 AM | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of PDS Biotechnology in a report on Wednesday.June 11, 2025 | marketbeat.comPDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCCJune 9, 2025 | globenewswire.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society ...June 3, 2025 | morningstar.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2025 | globenewswire.comPDS Biotechnology files to sell 9.82M shares of common stock for holdersMay 28, 2025 | msn.comWall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"Wall Street Zen upgraded PDS Biotechnology from a "sell" rating to a "hold" rating in a research report on Saturday.May 26, 2025 | marketbeat.comQ2 EPS Estimates for PDS Biotechnology Increased by B. RileyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at B. Riley increased their Q2 2025 earnings per share estimates for shares of PDS Biotechnology in a report released on Monday, May 19th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.23) per share foMay 24, 2025 | marketbeat.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...May 23, 2025 | uk.finance.yahoo.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | globenewswire.comPDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comEarnings call transcript: PDS Biotech’s Q1 2025 results show reduced lossesMay 16, 2025 | uk.investing.comPDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | finance.yahoo.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comPDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate UpdateMay 14, 2025 | globenewswire.comInsights Ahead: PDS Biotechnology's Quarterly EarningsMay 14, 2025 | benzinga.comPDS Biotechnology (PDSB) to Release Earnings on WednesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-pds-biotechnology-co-stock/)May 11, 2025 | marketbeat.comPDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comPDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual MeetingMay 8, 2025 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comPDS Biotechnology price target lowered to $5 from $7 at B. RileyApril 26, 2025 | markets.businessinsider.comB. Riley Predicts Stronger Earnings for PDS BiotechnologyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at B. Riley increased their Q1 2025 earnings per share (EPS) estimates for PDS Biotechnology in a note issued to investors on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0April 26, 2025 | marketbeat.comPDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comPDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual MeetingApril 16, 2025 | globenewswire.comPDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025April 8, 2025 | globenewswire.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comAlliance Global Partners Remains a Buy on PDS Biotechnology (PDSB)March 29, 2025 | markets.businessinsider.comPDS Biotechnology price target lowered to $13 from $21 at H.C. WainwrightMarch 27, 2025 | markets.businessinsider.comPDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays BearishMarch 27, 2025 | msn.comPDS Biotechnology Corporation: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs UpdateMarch 27, 2025 | finanznachrichten.dePDS Biotechnology Corporation CEO to Present at 2025 CAGLA NeauxCancer Conference in New OrleansMarch 27, 2025 | nasdaq.comA Look at PDS Biotechnology's Upcoming Earnings ReportMarch 27, 2025 | benzinga.comPDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comPDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs UpdateMarch 27, 2025 | globenewswire.comPDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer ConferenceMarch 25, 2025 | globenewswire.comPDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | uk.finance.yahoo.comShort Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Grows By 20.7%PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 4,670,000 shares, an increase of 20.7% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 630,100 shares, the days-to-cover ratio is presently 7.4 days. Approximately 13.8% of the shares of the stock are short sold.March 19, 2025 | marketbeat.comPDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on WednesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial ResultsMarch 18, 2025 | globenewswire.comPDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 comboMarch 13, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)March 13, 2025 | markets.businessinsider.comPDS Biotech gets IND application clearance for colorectal cancer treatmentMarch 13, 2025 | msn.comPDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal CancerMarch 13, 2025 | globenewswire.comPDS Biotech Leadership to Participate in March ConferencesMarch 11, 2025 | globenewswire.comPDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPVMarch 7, 2025 | markets.businessinsider.comPDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck CancerMarch 7, 2025 | globenewswire.com Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address PDSB Media Mentions By Week PDSB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PDSB News Sentiment▼0.080.89▲Average Medical News Sentiment PDSB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PDSB Articles This Week▼112▲PDSB Articles Average Week Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALLO News Today TRDA News Today GLUE News Today GOSS News Today OLMA News Today CGC News Today CADL News Today TNXP News Today PROK News Today ANNX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PDSB) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
